NF-kappaB Inhibitors that Prevent Foam Cell Formation and Atherosclerotic Plaque Accumulation
- UNCG Author/Contributor (non-UNCG co-authors, if there are any, appear on document)
- Anthony Dellinger (Creator)
- Christopher Kepley, Associate Professor (Creator)
- Institution
- The University of North Carolina at Greensboro (UNCG )
- Web Site: http://library.uncg.edu/
Abstract: The transformation of monocyte-derived macrophages into lipid-laden foam cells is one inflammatory process underlying atherosclerotic disease. Previous studies have demonstrated that fullerene derivatives (FDs) have inflammation-blunting properties. Thus, it was hypothesized that FD could inhibit the transformation process underlying foam cell formation. Fullerene derivatives inhibited the phorbol myristic acid/oxidized low-density lipoprotein-induced differentiation of macrophages into foam cells as determined by lipid staining and morphology. Lipoprotein-induced generation of TNF-a, C5a-induced MC activation, ICAM-1 driven adhesion, and CD36 expression were significantly inhibited in FD treated cells compared to non-treated cells. Inhibition appeared to be mediated through the NF-kappaB pathway as FD reduced expression of NF-kappaB and atherosclerosis-associated genes. Compared to controls, FD dramatically inhibited plaque formation in arteries of apolipoprotein E null mice. Thus, FD may be an unrecognized therapy to prevent atherosclerotic lesions via inhibition of foam cell formation and MC stabilization.
NF-kappaB Inhibitors that Prevent Foam Cell Formation and Atherosclerotic Plaque Accumulation
PDF (Portable Document Format)
986 KB
Created on 8/19/2019
Views: 233
Additional Information
- Publication
- Nanomedicine: Nanotechnology, Biology and Medicine, 2017 Aug;13(6):2037-2048
- Language: English
- Date: 2017
- Keywords
- Atherosclerosis, NF-kappaB, Foam cells, Fullerenes, Low-density lipoprotein